Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 8
2004 3
2005 10
2006 6
2007 7
2008 9
2009 6
2010 6
2011 5
2012 5
2013 6
2014 7
2015 7
2016 8
2017 12
2018 14
2019 11
2020 13
2021 11
2022 13
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers.
Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, Subramanian S, Starr TK, Fontana E, Pandey R, Lenz HJ, Shields AF, Nabhan C, Oberley M, Seeber A, El-Deiry W. Lou E, et al. Among authors: shields af. Mol Ther Oncol. 2024 Feb 28;32(1):200786. doi: 10.1016/j.omton.2024.200786. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596288 Free PMC article.
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Gallois C, et al. Among authors: shields af. J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326. Online ahead of print. J Clin Oncol. 2024. PMID: 38547438
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. Among authors: shields af. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial.
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
Khushman MM, Toboni MD, Xiu J, Manne U, Farrell A, Lou E, Shields AF, Philip PA, Salem ME, Abraham J, Spetzler D, Marshall J, Jayachandran P, Hall MJ, Lenz HJ, Sahin IH, Seeber A, Powell MA. Khushman MM, et al. Among authors: shields af. Clin Cancer Res. 2024 May 1;30(9):1906-1915. doi: 10.1158/1078-0432.CCR-23-3004. Clin Cancer Res. 2024. PMID: 38350001
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. Battaglin F, et al. Among authors: shields af. J Immunother Cancer. 2024 Jan 11;12(1):e007939. doi: 10.1136/jitc-2023-007939. J Immunother Cancer. 2024. PMID: 38212126 Free PMC article.
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, Dyson G, Kim S, Mzannar Y, Azar I, Odisho T, Mohamed A, Landesman Y, Kim S, Beydoun R, Mohammad RM, Philip PA, Shields AF, Azmi AS. Uddin MH, et al. Among authors: shields af. Clin Transl Med. 2023 Dec;13(12):e1513. doi: 10.1002/ctm2.1513. Clin Transl Med. 2023. PMID: 38131168 Free PMC article.
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Khan HY, et al. Among authors: shields af. Mol Cancer Ther. 2023 Dec 1;22(12):1422-1433. doi: 10.1158/1535-7163.MCT-23-0251. Mol Cancer Ther. 2023. PMID: 37703579 Free PMC article.
169 results